Last edition
News about "Cardiometabolic Diseases"
Pfizer to Acquire Metsera, Expand Obesity and Cardiometabolic Drug Pipeline
Pfizer is set to acquire Metsera, a clinical-stage biopharmaceutical company focused on developing the next generation of medicines for obesity and cardiometabolic diseases.
Cardiometabolic Diseases | 23/09/2025 | By Dineshwori
Superluminal and Eli Lilly Partner on Next-Gen Cardiometabolic and Obesity Treatments
Superluminal Medicines has announced a collaboration with Eli Lilly and Company to advance small molecule therapeutics for cardiometabolic diseases and obesity.
Cardiometabolic Diseases | 16/08/2025 | By Dineshwori | 101
TUL Signs Exclusive License Deal with Novo Nordisk for UBT251
Under the license agreement, Novo Nordisk will obtain exclusive worldwide rights (excluding Chinese mainland, Hong Kong, Macau, and Taiwan) to develop, manufacture, and commercialize UBT251.
Cardiometabolic Diseases | 25/03/2025 | By Aishwarya | 250
Valo Health and Novo Nordisk to Develop Novel Treatments for Cardiometabolic Diseases
The expanded collaboration will continue to leverage the capabilities of Valo’s Opal Computational Platform, as well as key joint capabilities in human data and genetics with Novo Nordisk’s expertise in cardiometabolic diseases.
Cardiometabolic Diseases | 09/01/2025 | By Aishwarya | 368
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy